Lyra Therapeutics (LYRA) Equity Ratio (2019 - 2025)
Quarterly Equity Ratio fell 269.84% to 0.3 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.3 through Dec 2025, down 269.84% year-over-year, with the annual reading at 0.3 for FY2025, 269.84% down from the prior year.
Lyra Therapeutics' Equity Ratio history spans 7 years, with the latest figure at 0.3 for Q4 2025.
- Equity Ratio came in at 0.3 for Q4 2025, down from 0.1 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.93 in Q1 2021 to a low of 0.3 in Q4 2025.
- The 5-year median for Equity Ratio is 0.63 (2021), against an average of 0.48.
- Year-over-year, Equity Ratio skyrocketed 129.79% in 2021 and then tumbled 269.84% in 2025.
- Lyra Therapeutics' Equity Ratio stood at 0.63 in 2021, then increased by 17.41% to 0.73 in 2022, then dropped by 14.61% to 0.63 in 2023, then tumbled by 72.13% to 0.17 in 2024, then crashed by 269.84% to 0.3 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Equity Ratio are 0.3 (Q4 2025), 0.1 (Q3 2025), and 0.03 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 0.73 |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 0.77 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 0.21 |
| 10 | Lyra Therapeutics | - | - | - | -0.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.30 |
| Sep 30, 2025 | -0.10 |
| Jun 30, 2025 | 0.03 |
| Mar 31, 2025 | 0.07 |
| Dec 31, 2024 | 0.17 |
| Sep 30, 2024 | 0.26 |
| Jun 30, 2024 | 0.33 |
| Mar 31, 2024 | 0.55 |
| Dec 31, 2023 | 0.63 |
| Sep 30, 2023 | 0.70 |
| Jun 30, 2023 | 0.78 |
| Mar 31, 2023 | 0.70 |
| Dec 31, 2022 | 0.73 |
| Sep 30, 2022 | 0.78 |
| Jun 30, 2022 | 0.82 |
| Mar 31, 2022 | 0.49 |
| Dec 31, 2021 | 0.63 |
| Sep 30, 2021 | 0.70 |
| Jun 30, 2021 | 0.75 |
| Mar 31, 2021 | 0.93 |
| Dec 31, 2020 | 0.92 |
| Sep 30, 2020 | 0.93 |
| Jun 30, 2020 | 0.94 |
| Mar 31, 2020 | -3.11 |
| Dec 31, 2019 | -8.24 |